Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer

Clinical Trial to Evaluate Efficacy of Redifferentiation Therapy Using Alpha-lipoic Acid in Thyroid Cancer Patients With Decreased Radioactive Iodine Uptake

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01396733

Acronym

RALT

Enrollment

Registered

2011-07-19

Start date

2011-04-30

Completion date

2013-12-31

Last updated

2021-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Thyroid

Keywords

thyroid, cancer, redifferentiation, lipoic acid

Brief summary

Radioiodine (I-131) therapy is of proven efficacy for treatment of differentiated thyroid carcinoma (DTC). However, loss of differentiation in recurrent or metastatic DTC which decrease I-131 uptake may decrease the efficacy of I-131 therapy. Therefore, strategies to improve I-131 uptake are mandatory. This study is an open label clinical study to evaluate the effectiveness of alpha-lipoic acid (ALA) for improving I-131 uptake in recurrent or metastatic of DTC with defective I-131 uptake.

Interventions

DRUGalpha-lipoic acids

alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. aged 20 to 75 years 2. under birth control, if fertile women 3. Groups * who received radioactive iodine treatment for recurrent and metastatic thyroid cancer, and did not showed any uptake at post-therapeutic whole body scan * who planned to receive empirical radioactive treatment due to high expected recurrence

Exclusion criteria

* allergic to alpha-lipoic acid * severe heart failure, lung disease, or end-stage renal disease * liver function abnormalities (x2.5 above normal limits) * neuropsychologically unstable patients * previous history of drug medication such as oral steroid, digoxin, theophylline, carbamazepine, valproic acid, phenobarbital, methotrexate, cyclosporin, tacrolimus within 3 months before this recruitment. * who is already taking alpha-lipoic acid for other purpose.

Design outcomes

Primary

Measure	Time frame
Increment of radioactive iodine uptake	3months after alpha-lipoic acid treatment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026